The latest price target for Medtronic (NYSE:MDT) was reported by Barclays on November 20, 2025. The analyst firm set a price target for $111.00 expecting MDT to rise to within 12 months (a possible 13.59% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Medtronic (NYSE:MDT) was provided by Barclays, and Medtronic maintained their overweight rating.

The last upgrade for Medtronic PLC happened on November 19, 2025 when Goldman Sachs raised their price target to $111. Goldman Sachs previously had a sell for Medtronic PLC.

The last downgrade for Medtronic PLC happened on August 14, 2024 when Stifel changed their price target from $100 to $85 for Medtronic PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medtronic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medtronic was filed on November 20, 2025 so you should expect the next rating to be made available sometime around November 20, 2026.

While ratings are subjective and will change, the latest Medtronic (MDT) rating was a maintained with a price target of $109.00 to $111.00. The current price Medtronic (MDT) is trading at is $97.72, which is out of the analyst’s predicted range.